Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Bought by Vestor Capital LLC

Vestor Capital LLC grew its holdings in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 196.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,541 shares of the biopharmaceutical company’s stock after buying an additional 74,640 shares during the period. Horizon Therapeutics Public accounts for about 1.2% of Vestor Capital LLC’s investment portfolio, making the stock its 29th biggest holding. Vestor Capital LLC’s holdings in Horizon Therapeutics Public were worth $11,840,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. raised its holdings in Horizon Therapeutics Public by 8.4% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 90,405 shares of the biopharmaceutical company’s stock worth $9,742,000 after purchasing an additional 6,971 shares in the last quarter. Gotham Asset Management LLC increased its holdings in shares of Horizon Therapeutics Public by 17.8% in the fourth quarter. Gotham Asset Management LLC now owns 8,076 shares of the biopharmaceutical company’s stock valued at $870,000 after buying an additional 1,221 shares in the last quarter. FDx Advisors Inc. increased its holdings in shares of Horizon Therapeutics Public by 4.0% in the fourth quarter. FDx Advisors Inc. now owns 16,131 shares of the biopharmaceutical company’s stock valued at $1,738,000 after buying an additional 622 shares in the last quarter. Cozad Asset Management Inc. bought a new position in shares of Horizon Therapeutics Public in the first quarter valued at $3,891,000. Finally, Arizona State Retirement System increased its holdings in shares of Horizon Therapeutics Public by 2.7% in the first quarter. Arizona State Retirement System now owns 59,981 shares of the biopharmaceutical company’s stock valued at $6,311,000 after buying an additional 1,554 shares in the last quarter. Institutional investors own 88.39% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Andy Pasternak sold 762 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $85.36, for a total transaction of $65,044.32. Following the sale, the executive vice president now directly owns 38,897 shares of the company’s stock, valued at $3,320,247.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Timothy P. Walbert sold 25,000 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. Following the transaction, the chief executive officer now directly owns 460,549 shares in the company, valued at $41,449,410. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Andy Pasternak sold 762 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $85.36, for a total transaction of $65,044.32. Following the completion of the sale, the executive vice president now owns 38,897 shares in the company, valued at $3,320,247.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 98,384 shares of company stock valued at $8,934,633. 2.50% of the stock is currently owned by insiders.

Horizon Therapeutics Public Price Performance

NASDAQ HZNP traded up $2.60 on Friday, reaching $69.60. The company’s stock had a trading volume of 5,969,701 shares, compared to its average volume of 2,754,390. The company has a current ratio of 4.05, a quick ratio of 3.30 and a debt-to-equity ratio of 0.52. The firm has a market cap of $16.03 billion, a PE ratio of 21.48, a price-to-earnings-growth ratio of 1.13 and a beta of 1.12. Horizon Therapeutics Public Limited has a 52 week low of $60.76 and a 52 week high of $120.54. The business has a 50-day moving average price of $83.03 and a 200 day moving average price of $93.34.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.29). The firm had revenue of $876.40 million for the quarter, compared to the consensus estimate of $938.82 million. Horizon Therapeutics Public had a return on equity of 27.90% and a net margin of 20.06%. Horizon Therapeutics Public’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 earnings per share. Sell-side analysts expect that Horizon Therapeutics Public Limited will post 5.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on HZNP. BMO Capital Markets dropped their price target on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating on the stock in a report on Thursday. The Goldman Sachs Group lowered their price objective on shares of Horizon Therapeutics Public from $164.00 to $144.00 and set a “buy” rating on the stock in a research report on Thursday. Wells Fargo & Company reiterated a “buy” rating and set a $133.00 price objective on shares of Horizon Therapeutics Public in a research report on Friday, April 8th. Oppenheimer reiterated a “buy” rating and set a $140.00 price objective on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. Finally, StockNews.com cut shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $117.22.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Read More

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.